cGVHD Management in Focus: Emerging Therapies, Guidelines, and Pharmacist-Led Strategies

Panelists discuss how early diagnosis, evolving treatment strategies, and pharmacist-led interventions are advancing chronic graft-vs-host disease (cGVHD) management by addressing unmet needs, improving care coordination, and enhancing patient access to emerging therapies.

Panelists discuss how second-line therapy selection and individualized care strategies are essential in chronic graft-vs-host disease (cGVHD) management, emphasizing the need to reduce steroid-related toxicity, address patient-specific factors, and leverage pharmacist expertise to optimize outcomes.

Panelists discuss how recent FDA approvals and evolving evidence for second-line treatments, including ruxolitinib, ibrutinib, and belumosudil, are reshaping chronic graft-vs-host disease (cGVHD) management by offering tailored, evidence-based options for steroid-refractory patients.

Panelists discuss how factors such as patient preferences, disease severity, organ-specific involvement, and adverse effect profiles influence the selection of second-line therapies for steroid-refractory chronic graft-vs-host disease (cGVHD) in the context of multiple FDA-approved agents.

Panelists discuss how factors such as patient preferences, disease severity, organ-specific involvement, and adverse effect profiles influence the selection of second-line therapies for steroid-refractory chronic graft-vs-host disease (cGVHD) in the context of multiple FDA-approved agents.

Panelists discuss how evolving treatment pathways at Emory Healthcare, including earlier use of emerging therapies and off-label combination treatments, are shaping the management of chronic graft-vs-host disease (cGVHD), with an emphasis on personalizing therapy based on real-world data and patient-specific factors.

Panelists discuss how pharmacists improve patient outcomes in chronic graft-vs-host disease (cGVHD) by addressing accessibility and tolerability challenges, optimizing drug regimens, managing adherence, and fostering trust with patients to ensure consistent therapy and long-term success.

Panelists discuss how pharmacists are essential in managing chronic graft-vs-host disease (cGVHD) by addressing challenges like toxicity, financial and logistical barriers, and a lack of awareness, while advocating for patient education, collaboration with health care teams, and ensuring access to necessary therapies.

Panelists discuss how collaboration between pharmacists and health care providers is essential for optimizing treatment outcomes in chronic graft-vs-host disease (cGVHD), emphasizing the importance of education, symptom management, and a multidisciplinary approach to ensure comprehensive, patient-tailored care.

Panelists discuss how advancing chronic graft-vs-host disease (cGVHD) management involves improving steroid response rates, exploring combination therapies, utilizing biomarkers for personalized treatment, and striving for steroid-free first-line options to enhance patient outcomes and reduce long-term adverse effects.